Contrive Datum Insights has published "Osteoarthritispain Market Size, Share & Industry Analysis, By Type (Oral, Non-Oral), Application (Pharmacy, Hospital, Other), Age group (Geriatric Population, Adult Population, Pediatric Population), Drug class (NSAIDs, Opioid Analgesics, Corticosteroids, Hyaluronic Acid Injections, Disease-Modifying OA Drugs), Joint / indication (Knee OA, Hip OA, Hand & Other Joints OA), and Regional Forecast, 2026-2034". The study sizes the osteoarthritis pain management osteoarthritispain market at USD 8.9 billion in 2025 and projects growth from USD 9.55 billion in 2026 to USD 16.2 billion by 2034, a compound annual growth rate of 6.83% across the forecast period.
Osteoarthritis pain management covers the medicines and injectable therapies used to relieve joint pain and slow functional decline in patients with degenerative joint disease, spanning oral analgesics and anti-inflammatories, topical formulations, and intra-articular injections such as corticosteroids and hyaluronic acid. Buyers range from hospital pharmacies and orthopedic and rheumatology clinics stocking injectable therapies to retail and online pharmacies dispensing oral and topical products directly to patients managing a chronic condition at home.
Rising global prevalence of osteoarthritis among aging populations
Rising global prevalence of osteoarthritis among aging populations is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 6.83% a year, the type lines exposed to it move fastest: Non-Oral compounds at 8.24%, taking its share of revenue from 40.86% to 46% and its value from USD 3.636 billion to USD 7.452 billion.
Where the forecast could be beaten: bull assumes disease-modifying OA drug approvals accelerate and reimbursement expands faster than the base case across major markets. The study puts that case at USD 17.82 billion in 2034, against USD 16.2 billion in the base.
Against that, bear assumes reimbursement tightens further and generic pricing pressure on NSAID and corticosteroid categories outpaces the base case. On that reading 2034 revenue stops at USD 14.58 billion. The weight of the problem sits in Oral: 59.14% of 2025 revenue growing at 5.75%, well under the market's 6.83%.
The Competitive Split Runs by Type
Suppliers here are separated by type, not by geography. The incumbent position is Oral: 59.14% of 2025 revenue, USD 5.264 billion, and still 54% in 2034. The contested position is Non-Oral at 8.24% growth. Few suppliers hold both, which is why a market of USD 8.9 billion supports as many participants as it does.
Additional Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Application | Pharmacy | 52% · USD 4.628 billion | Other 10.58% |
| Age group | Geriatric Population | 58% · USD 5.162 billion | — |
| Drug class | NSAIDs | 38% · USD 3.382 billion | Disease-Modifying OA Drugs 13.38% |
| Joint / indication | Knee OA | 56% · USD 4.984 billion | Hand & Other Joints OA 8.94% |
- North America was the largest region in 2025, holding 38.21% of global revenue at USD 3.401 billion and reaching USD 5.67 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 23.5% in 2025 to 28% in 2034, with revenue growing from USD 2.092 billion to USD 4.536 billion.
- Middle East and Africa remains the smallest region throughout, at 5.5% of 2025 revenue and 5.5% by 2034.
- Oral was the leading type line in 2025, taking 59.14% of revenue at USD 5.264 billion.
- The fastest type line is Non-Oral, forecast to compound at 8.24% through the period.
- The United States is the largest single country market at USD 2.85 billion in 2025, 32.02% of global revenue.
The study covers five axes, by type, and by application, age group, drug class and joint / indication, reporting revenue and a growth rate for every line in every year from 2020 to 2034, with bear, base and bull scenarios on the headline total at USD 14.58 billion and USD 17.82 billion by 2034. Country-level detail is given for all five regions, together with the competitive landscape and the research methodology. Delivered as a PDF; request a free sample to review it.